Susquehanna International Group’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-201,400
| Closed | -$20.5M | – | 13346 |
|
|
2023
Q2 | $20.5M | Sell |
201,400
-206,600
| -51% | -$19.6M | ﹤0.01% | 1689 |
|
|
2023
Q1 | $37.1M | Buy |
408,000
+265,600
| +187% | +$15.6M | 0.01% | 1148 |
|
|
2022
Q4 | $5.41M | Sell |
142,400
-3,800
| -3% | -$131K | ﹤0.01% | 3119 |
|
|
2022
Q3 | $3.67M | Buy |
146,200
+36,800
| +34% | +$1.02M | ﹤0.01% | 3683 |
|
|
2022
Q2 | $3.33M | Sell |
109,400
-124,200
| -53% | -$3.71M | ﹤0.01% | 3889 |
|
|
2022
Q1 | $7.65M | Buy |
233,600
+54,800
| +31% | +$1.63M | ﹤0.01% | 2925 |
|
|
2021
Q4 | $4.71M | Buy |
178,800
+152,700
| +585% | +$11.8M | ﹤0.01% | 3846 |
|
|
2021
Q3 | $2.63M | Sell |
26,100
-13,400
| -34% | -$1.57M | ﹤0.01% | 5244 |
|
|
2021
Q2 | $5.59M | Buy |
39,500
+3,500
| +10% | +$395K | ﹤0.01% | 3840 |
|
|
2021
Q1 | $3.59M | Sell |
36,000
-8,600
| -19% | -$1M | ﹤0.01% | 4573 |
|
|
2020
Q4 | $5.51M | Sell |
44,600
-23,100
| -34% | -$3.04M | ﹤0.01% | 3273 |
|
|
2020
Q3 | $6.59M | Sell |
67,700
-32,400
| -32% | -$4.05M | ﹤0.01% | 2722 |
|
|
2020
Q2 | $15.6M | Sell |
100,100
-36,300
| -27% | -$5.52M | ﹤0.01% | 1663 |
|
|
2020
Q1 | $19.7M | Buy |
136,400
+17,000
| +14% | +$3.28M | 0.01% | 1177 |
|
|
2019
Q4 | $24.4M | Buy |
119,400
+15,500
| +15% | +$2.83M | 0.01% | 1250 |
|
|
2019
Q3 | $8.34M | Buy |
103,900
+41,000
| +65% | +$3.48M | ﹤0.01% | 2168 |
|
|
2019
Q2 | $5.93M | Sell |
62,900
-42,100
| -40% | -$3.63M | ﹤0.01% | 2485 |
|
|
2019
Q1 | $8.97M | Buy |
105,000
+58,500
| +126% | +$4.86M | ﹤0.01% | 1841 |
|
|
2018
Q4 | $2.61M | Sell |
46,500
-51,200
| -52% | -$3.13M | ﹤0.01% | 3127 |
|
|
2018
Q3 | $7.99M | Buy |
97,700
+43,500
| +80% | +$3.07M | ﹤0.01% | 2156 |
|
|
2018
Q2 | $1.9M | Buy |
54,200
+35,700
| +193% | +$1.09M | ﹤0.01% | 4101 |
|
|
2018
Q1 | $379K | Buy |
18,500
+9,400
| +103% | +$242K | ﹤0.01% | 7199 |
|
|
2017
Q4 | $258K | Buy |
+9,100
| New | +$254K | ﹤0.01% | 7837 |
|
Other funds holding RETA
Susquehanna International Group's RETA Position: Q3 2023 in Review
Susquehanna International Group sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 84,059 shares — an estimated $8.57M sold.
Susquehanna International Group first reported a position in RETA in Q2 2019 and held it in 14 quarters. The position peaked at $13M in Q4 2019. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.
- Susquehanna International Group reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
- Susquehanna International Group sold 84,059 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $8.57M.
- Susquehanna International Group first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q2 2019 and held it in 14 quarters.
- Susquehanna International Group's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $13M in Q4 2019.
- 2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.
Based on Susquehanna International Group's 13F filing for Q3 2023, filed 14 Nov 2023.